Other
Immunomodulation
0
Pipeline Programs↗
3
Active Trials↗
2
Companies Involved↗
Immunomodulation is an early-stage landscape with 0 programs across 2 companies. The most active players are OM Pharma SA, Eledon Pharmaceuticals.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
19
clinical trials
Completed9 · 47%
Terminated4 · 21%
Withdrawn3 · 16%
Recruiting2 · 11%
Active, not recruiting1 · 5%
Clinical Trials
Trial Activity
19 trials
Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy
Recruiting·—·Phase 2·NCT02310867·50 enrolled
GM-CSF for Immunomodulation Following Trauma (GIFT) Study
Completed·—·Phase 4·NCT01495637·108 enrolled
Synergism of Immunomodulation and Tumor Ablation
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT03101475·22 enrolled
Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir
Completed·—·Phase 2·NCT00976404·28 enrolled
Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)
Completed·National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)·Phase 1/2·NCT02338999·88 enrolled
Novel Strategies to Improve Immunomodulation and Non-invasive Clinical Monitoring in VCA
Terminated·—·Phase 1·NCT03241719·2 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)